Shared publicly  - 
New method of bacterial cell engineering can produce better, cheaper drug therapies

Therapeutic proteins, which provide cutting-edge treatments of cancer, diabetes and countless other diseases, are among today's most widely consumed biopharmaceuticals. By introducing bottom-up carbohydrate engineering into common bacterial cells, Cornell researchers have discovered a way to make these drugs cheaper and safer.

A research team led by Matthew DeLisa, associate professor of chemical and biomolecular engineering, has invented a novel method for engineering human therapeutic glycoproteins simply and quickly using E. coli bacteria as a platform. Their work is detailed online March 25 in Nature Chemical Biology.

read more:﻿
Gerd Moe-Behrens's profile photo
Add a comment...